b'TRG MRD Clonality AssayBackgroundCombinations of chemotherapy, radiation therapy andlocus become rearranged through the random deletion bone marrow transplantation are potentially curativeor insertion of nucleotides within the junctional region, for several hematologic malignancies. However, in somegenerating specific and unique sequences within each patients, occult tumor cells exist and are thought to increaselymphocyte. Cancer cells that arise from alterations in the patients risk of relapse. 1These subclinical levels ofsingle lymphoid precursors acquire clonal TRG junctional residual leukemia are termed minimal residual diseaseregions which can be used as tumor-specific markers. 2,3(MRD) and can be evaluated using sensitive assays.MRD detection by Next-Generation Sequencing has The tracking of antigen-receptor gene rearrangementsdemonstrated utility in predicting clinical outcomes for clonality analyses and MRD monitoring can be appliedand in generating clinically actionable results, allowing to virtually all patients. During early T-cell development,early intervention, confirmation of disease status prior to the germline variable (V), constant (C), and joining (J)transplant, and increased confidence in remission status. fragments of the T Cell Receptor Gamma (TRG) References1.Rezuke WN et al. (1997) Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications.Clin Chem 43:1814-23.2.Gazzola A et al. (2014) The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. TherAdv Hematol. 5:35-47.3.Gonzlez D et al. (2007) Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 110:3112-21. 46'